September 19th 2024
"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.
September 16th 2024
Pivotal olaparib/abiraterone mCRPC data published in New England Journal of Medicine Evidence
June 22nd 2022The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to frontline abiraterone acetate significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
UCSF prostate cancer specialist inducted into annual class of Giants of Cancer Care
June 21st 2022Eric J. Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.
FDA clears hyaluronic acid rectal spacer for use during prostate radiotherapy
June 15th 2022Barrigel, which is made from Non-Animal Stabilized Hyaluronic Acid (NASHA), is used to separate and increase the distance between the anterior rectal wall and the prostate when the patient is receiving radiotherapy.
Dr. Armstrong on recent ARCHES data in metastatic hormone-sensitive prostate cancer
June 6th 2022“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.
Dr. Kibel discusses TRUS-guided and transperineal prostate biopsy
June 2nd 2022"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.
At a glance: Single-port robot-assisted transvesical prostatectomies
June 1st 2022“Using the single-port robot with the transvesical approach allows us to go directly into the bladder, this means that we avoid the intraperitoneal cavity, which is not feasible with the multiport approach. This has led to less pain and postoperative ileus because the bowels stay intact,” says Jihad Kaouk, MD.
Urology Times 50 Innovations Series: Dr. Jennifer Linehan on HIFU for prostate cancer
May 25th 2022"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.